France’s second-largest pharmaceutical company, Servier Group, opened its first U.S.-based commercial subsidiary in Boston this week, with plans to double the headcount over the next five years.
Servier Pharmaceuticals opened its doors at 200 Pier 4 Blvd. Thursday. The 14,500-square-foot site will house Servier's work developing and commercializing treatments for gastrointestinal and liquid cancers like leukemia using immune system-leveraging approaches including CAR-T and monoclonal antibodies.…
